Japan, July 14 -- DECIBEL THERAPEUTICS INC,REGENERON PHARMACEUTICALS INC has got intellectual property rights for 'COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS.' Other related details are as follows:
Application Number: JP,2025-064211
Category (FI): A61K35/76,A61P27/16,C12N15/11@Z,A61K48/00,A61K38/17,C12N15/12,C12N15/864,100@Z
Stage: PROBLEM TO BE SOLVED: To provide compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly, forms of the disease that are associated with a mutation in otoferlin (OTOE), by way of OTOE gene therapy.SOLUTION: The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOE isoform 5 protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOE isoform 5 protein. These vectors can be used to increase the expression of OTOE in a subject, such as a human subject suffering from sensorineural hearing loss.SELECTED DRAWING: Figure 1A (Grant)
Filing Date: April 9, 2025
Publication Date: July 15, 2025
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
